Structure Therapeutics

Developing accessible oral small molecule therapies for the treatment of chronic diseases including obesity and related diseases.

[Structure Therapeutics @StructureTx]

Today, we reported financial results for the third quarter ended September 30, 2026, and provided a business update across our oral small molecule #obesity portfolio. Read the full announcement: https://t.co/2VzS97j74v

[Structure Therapeutics @StructureTx]

Our team will participate in a fireside chat at the Jefferies Global Healthcare Conference, held November 16-19, 2026 in London. The live and archived webcasts will be accessible from our website and replays will be available for at least 90 days. Read the announcement: https://t.co/si58iHoLEH

[Structure Therapeutics @StructureTx]

We were in Milan last week for #EASD2026! It was incredible to come together with experts and advocates from across the globe to convene on the latest research and innovations for patients. We were proud to present the positive 72-week data for our investigational therapy for chronic weight management, aleniglipron, in the ACCESS open-label extension (OLE) clinical trial. Thanks to @EASDnews for another impactful meeting.

[Structure Therapeutics @StructureTx]

The Structure team traded the office for the starting line at this year’s San Francisco J.P. Morgan Corporate Challenge! It was a great opportunity to come together outside of our day-to-day, enjoy some friendly competition, and share a few miles as a team. Thanks to everyone who joined us for an evening of movement, connection, and team spirit!
#JPMCC

[Structure Therapeutics @StructureTx]

We're pleased to report positive clinical results from our two lead product candidates: ACCG-2671, an oral small-molecule dual amylin and calcitonin receptor agonist (DACRA) and aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Together, these programs advance our goal of creating a best-in-industry oral chronic weight management portfolio for patients at different stages in their treatment journey. https://t.co/gk0kUnZ8ll

[Structure Therapeutics @StructureTx]

Today, we reported financial results for the second quarter ended June 30, 2026 and provided a business update including the initiation of the Phase 3 ACCOMPLISH program evaluating aleniglipron for the treatment of #obesity. Read more here: https://t.co/AAkJxlguYu

[Structure Therapeutics @StructureTx]

Thanks to everyone who stopped by our table at the @ObesityAction's Your Weight Matters National Convention! It was a privilege to connect with members of the #obesity community, share stories and focus on how these experiences shape the future of obesity care. We're grateful to the OAC for bringing together a community dedicated to education, advocacy and support. #YWM2026

[Structure Therapeutics @StructureTx]

We're proud to sponsor the @ObesityAction's Your Weight Matters National Convention, where individuals, families, healthcare professionals, and advocates come together to advance education, support, and conversations around #obesity care. If you're attending #YWM2026, stop by our table to learn more about our mission to make medicines more accessible.

[Structure Therapeutics @StructureTx]

#ICYMI

🔎 Publication in Nature Medicine Highlights Phase 2b ACCESS Program of Aleniglipron for Obesity: https://t.co/BToNnyiBOD

📺 CEO Raymond Stevens joins CNBC: https://t.co/EA9RVRkude

[Structure Therapeutics @StructureTx]

Our CEO joined @CNBC's at #ADASciSessions to discuss why accessibility is at the heart of the evolving weight loss market and how our once-daily oral #GLP1 aleniglipron, with potential market launch expected by 2029, is designed to reach more patients globally. https://t.co/BO1e6MAnfl

[Structure Therapeutics @StructureTx]

A strong week at #ADA2026. Aleniglipron ACCESS data opened the conference with a Nature Medicine publication same day with up to 16.2% body weight loss, no plateau, Phase 3 on track for Q3 2026.

Two late-breaking amylin posters and a @CNBC appearance rounded out the week. See the highlights below. 👉

[Structure Therapeutics @StructureTx]

Our CEO joined @CNBC's at #ADASciSessions to discuss why accessibility is at the heart of the evolving weight loss market and how our once-daily oral #GLP1 aleniglipron, with potential market launch expected by 2029, is designed to reach more patients globally. https://t.co/BO1e6MAnfl

[Structure Therapeutics @StructureTx]

Data from the Phase 2b ACCESS trial of aleniglipron, our once-daily oral #GLP1 pill, has been published in Nature Medicine and was presented today at the 86th #ADASciSessions.

Key findings include:
➡️Up to 16.2% body weight loss at 56 weeks with continued weight loss and no apparent plateau, and
➡️a low 10.4% overall discontinuation rate.

Phase 3 remains on track for Q3 2026.

Read more: https://t.co/LUCeM7UP3g

[Structure Therapeutics @StructureTx]

The patient voice matters at every table. It guides how we partner with patients and physicians and shape programs to make a real difference for people living with #obesity. Our executive director, medical affairs & advocacy engagement shares more below. ⬇️

[Structure Therapeutics @StructureTx]

On #ClinicalTrialsDay, we're thinking about the participants in our studies, the investigators, coordinators, and study teams beside them, and the families who make every visit possible.

Our mission is to deliver oral #smallmolecule medicines that are more scalable, manufacturable, and broadly accessible because innovation only matters if it reaches the patients it's meant to serve.

[Structure Therapeutics @StructureTx]

Today, we reported financial results for the first quarter ended March 31, 2026, and provided a business update. Top highlights include:

📉Positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point;
🔎Aleniglipron, amylin and combination data to be presented at the 86th #ADASciSessions
▶️Data from ACCESS OLE expected in Q3 2026, and ongoing body composition and type 2 diabetes/obesity studies expected in Q4 2026;
📊Initial data from Phase 1 SAD study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of MAD study expected in Q3 2026;

Read the full announcement: https://t.co/YS7nvQcFlR

[Structure Therapeutics @StructureTx]

We’re heading to the 86th #ADASciSessions to showcase aleniglipron in multiple presentations share new data across ACCESS, including its class-leading efficacy along with tolerability and safety data for aleniglipron, plus new amylin #smallmolecule and preclinical combination data.

View the details here: https://t.co/15VENgIjqE

[Structure Therapeutics @StructureTx]

We continue to remember Danielle Keatley, a deeply respected and valued member of our biotech community. She had a genuine passion for our company's mission to expand access to medicines, and her presence left a lasting impact on those who worked alongside her. We'll carry her memory with us and remain committed to honoring her legacy.

In her honor, a memorial fund has been established, and a celebration of life will be held on Sunday, April 26. You can find more about Danielle’s life, along with details on the memorial fund and upcoming celebration of life, here.
https://t.co/5RQ8IF5k0e

[Structure Therapeutics @StructureTx]

We’re pleased to welcome Matthew Lang, J.D. as Chief Operating Officer and General Counsel at Structure Therapeutics.

With 15+ years of leadership across global biopharma, his experience will support our next phase of growth as we advance aleniglipron into Phase 3.

Read more: https://t.co/7cza5J4WW5

[Structure Therapeutics @StructureTx]

Our CEO appeared on @SquawkStreet to discuss the latest Phase 2 data for aleniglipron, our once-daily #GLP1 oral pill, which demonstrated best-in-class efficacy and off-target safety, and low, single-digit discontinuation rates. The progress we’re seeing broadly reinforces that oral approaches to #obesity are becoming effective.

[Squawk on the Street @SquawkStreet]

CNBC EXCLUSIVE: Structure Therapeutics CEO on the company's oral GLP-1 opportunity $GPCR https://t.co/at5sKcKs0f